Hormone therapy and ovarian cancer: Incidence and survival

Cancer Causes and Control

Volumn 19, Issue 6, 2008, Pages 605-613

  Wernli, Karen J ^a   Newcomb, Polly A ^a,b   Hampton, John M ^b   Trentham Dietz, Amy ^b   Egan, Kathleen M ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Hormone therapy; Incidence; Ovarian cancer; Survival

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MASSACHUSETTS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; WISCONSIN;

EID: 46449102314     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-008-9125-x     Document Type: Article

References (39)

1. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47-53
2. Writing Group for the Women's Health Initiative I (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the women's health initiative randomized controlled trial. JAMA 288:321-333
3. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncology 6:552-553
4. Cook LS, Weiss NS, Doherty JA, Chen C (2006) Endometrial cancer. In: Schottenfeld D, Fraumeni JF (eds), Cancer epidemiology and prevention. Oxford, Oxford Press
5. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE (2007) A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 96:151-156
6. Mills PK, Riordan DG, Cress RD, Goldsmith DF (2005) Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29:124-132
7. Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:1703-1710
8. Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 112:130-134
9. Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ (1997) Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89:1012-1016
10. Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144:363-372
11. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB (2002) Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86:118-123
12. Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472-479
13. Anderson GL, Judd HL, Kaunitz AM et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women's health initiative randomized trial. JAMA 290:1739-1748
14. Lacey JV, Jr., Brinton LA, Leitzmann MF et al (2006) Menopausal hormone therapy and ovarian cancer risk in the national institutes of health-AARP diet and health study cohort. J Natl Cancer Inst 98:1397-1405
15. Lacey JV, Jr., Mink PJ, Lubin JH et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334-341
16. Eeles RA, Tan S, Wiltshaw E et al (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259-262
17. Bebar S, Ursic-Vrscaj M (2000) Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 21:192-196
18. Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 8:70-75
19. Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 86:1013-1018
20. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. (1995) Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141:828-835
21. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460-1465
22. Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119:2907-2915
23. Trentham-Dietz A, Newcomb PA, Egan KM et al (2000) Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control 11:533-542
24. Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton JM, Egan KM (2007) Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev 16:236-243
25. Calle EE, Terrell DD (1993) Utility of the national death index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 137:235-241
26. Breslow NE, Day NE (1980) Statistical methods in cancer research, Vol I. The analysis of case-control studies. IARC Scientific Publications, Lyon, pp 5-338
27. Breslow NE, Day NE (1987) Statistical methods in cancer research, Vol II-The design and analysis of cohort studies. IARC Scientific Publications, Lyon
28. Coughlin SS, Giustozzi A, Smith SJ, Lee NC (2000) A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53:367-375
29. Riman T, Dickman PW, Nilsson S et al (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94:497-504
30. Folsom AR, Anderson JP, Ross JA (2004) Estrogen replacement therapy and ovarian cancer. Epidemiology 15:100-104
31. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuck A (2005) Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 193:76-82
32. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH (2004) Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82:186-195
33. Purdie DM, Bain CJ, Siskind V et al (1999) Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81:559-563
34. Sherman ME, Carreon JD, Lacey JV, Jr., Devesa SS (2005) Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst 97:1700-1702
35. Luoto R, Raitanen J, Pukkala E, Anttila A (2004) Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953-2010. Br J Cancer 90:1756-1759
36. Redburn JC, Murphy MF (2001) Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales. Bjog 108:388-395
37. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774-1786
38. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61:6768-6776
39. Ries LAG, Melbert D, Krapcho M, et al (2007) SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site